Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of the study is to assess the pathologic complete remission rate (according to the Junker criteria regression IIB and III) after induction therapy with gefitinib D-12 to D -1 followed by docetaxel 75 mg/m2 and cisplatin 50 mg/m2 D1+2 q21d (or paclitaxel 200 mg/m² D1 and carboplatin AUC 6.0 D1) and intercalated gefitinib 250 mg D4 to D20 (cycles 1 + 2) and D4-D17 (cycle 3) in mediastinal/hilar lymph nodes as well as primary tumor.
Critère d'inclusion
- Patients with stage II, IIIA and IIIB non-squamous non-small-cell lung cancer with activating EGFR mutation